^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MaaT013

    i
    Other names: MaaT013, MaaT 013, fecal microbiota transfer, Autologous fecal microbiota transplant, MaaT-013
    Associations

    News

    Trials
    Company:
    MaaT Pharma
    Drug class:
    Microbiome modulator
    Related drugs:
    Associations

    News

    Trials
    28d
    ARES: MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients (clinicaltrials.gov)
    P3, N=66, Active, not recruiting, MaaT Pharma | Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> Nov 2025 | Trial primary completion date: Sep 2023 --> Nov 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Jakafi (ruxolitinib) • MaaT013
    over2years
    PICASSO: Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma (clinicaltrials.gov)
    P2, N=60, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • MaaT013
    over3years
    PICASSO: Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
    Clinical • New P2 trial
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • MaaT013